News Conference News TCT 2016 EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease Michael O'Riordan October 31, 2016
News Conference News TCT 2016 Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI Yael L. Maxwell October 31, 2016
News Conference News TCT 2016 Are Full, Formal Guidelines Still Useful in the Rapidly Changing TAVR Field? Todd Neale October 30, 2016
Presentation TCT 2016 Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide! Presenter: David R. Holmes Jr., Josep Rodés-Cabau, David Hildick-Smith October 30, 2016
Presentation TCT 2016 Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Stefan C. Bertog October 30, 2016
Presentation TCT 2016 Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR! Presenter: Russell A. Brandwein, Isaac George October 30, 2016
Presentation TCT 2016 Debate: TAVR for Low Risk Patients Is It time? YES, the Data Is Sufficient and Our Patients Want It! Presenter: Russell A. Brandwein, Susheel K. Kodali October 30, 2016
Presentation TCT 2016 Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes! Presenter: Patrick T. O'Gara, Alec S. Vahanian, Lars G. Svensson October 30, 2016
Presentation TCT 2016 Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma October 30, 2016
Presentation TCT 2016 Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack October 30, 2016
Presentation TCT 2016 Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study Presenter: Patrick T. O'Gara, Alec S. Vahanian, Neil E. Moat October 30, 2016
Presentation TCT 2016 Real-world Requirements and Expectations for TAVR in Lower Risk Patients Presenter: Patrick T. O'Gara, Alec S. Vahanian, Martin B. Leon October 30, 2016
Presentation TCT 2016 An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients Presenter: Patrick T. O'Gara, Alec S. Vahanian, Catherine M. Otto October 30, 2016
News Conference News TCT 2016 LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years Yael L. Maxwell October 30, 2016
Presentation TCT 2016 First Debate: Should The Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely Not - In No Universe Would That Be Considered Acceptable Care! Presenter: James S. Gammie, James B. Hermiller Jr., Alfredo Trento October 30, 2016
Presentation TCT 2016 First Debate: Should the Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely! - As Long as He Receives Truly Informed Consent by A Heart Team! Presenter: James S. Gammie, James B. Hermiller Jr., Brian K. Whisenant October 30, 2016
Presentation TCT 2016 TAVR 2016: Making the Case For New Patient Subsets (Low Risk, Bicuspid, etc.) Presenter: Marian C. Hawkey, Patricia Keegan October 30, 2016
News Conference News TCT 2016 YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients Michael O'Riordan October 29, 2016
News Conference News TCT 2016 Transcaval TAVR Presents New Option for Patients With Complex Anatomy Yael L. Maxwell October 29, 2016
News Conference News TCT 2016 Impella CP Fails to Show Benefit in Exploratory Study of Patients With Severe Cardiogenic Shock Todd Neale October 29, 2016